首页 > 最新文献

Euroasian Journal of Hepato-Gastroenterology最新文献

英文 中文
Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study. D2夹层时代胃癌的辅助治疗:来自多中心回顾性队列研究的现实经验。
Pub Date : 2021-07-01 DOI: 10.5005/jp-journals-10018-1343
Emre Yekedüz, İzzet Doğan, Sümerya D Birgi, Metin Keskin, Şule Karaman, Güngör Utkan, Senem Karabulut, Sancar Bayar, Hakan Akbulut, Salim Demirci, Serap Akyürek, Yüksel Ürün

Background: The role of radiotherapy in the adjuvant treatment of gastric cancer (GC) remains to be elucidated. This study aimed to assess the additional benefit of radiotherapy in the adjuvant treatment of GC.

Materials and methods: In this retrospective cohort study, we included 230 gastric adenocarcinoma patients who underwent D2 dissection between January 2004 and December 2019. Patients without R0 resection, who underwent metastasectomy at surgery, and treated with the neoadjuvant treatment were excluded. The co-primary endpoints were overall survival (OS) and disease-free survival (DFS). The secondary endpoints were the locoregional and distant metastasis risk and adverse events (AEs) leading to treatment discontinuation.

Results: One hundred and sixty-six and 64 patients were included in the chemoradiotherapy (CRT) and chemotherapy (ChT) arms, respectively. The median OS was 135.8 months [interquartile range (IQR): 99.4-172.2] and 97 months (IQR: 59.7-134.3) in the CRT and the ChT arms, respectively. No statistical significance was observed between the arms in OS (p = 0.3). Locoregional or distant recurrence rates were similar in each group. AEs leading to treatment discontinuation were higher in the CRT arm than in the ChT arm (13.2 vs 9.3%), and the difference between the arms was not statistically significant (p = 0.4).

Conclusion: In this real-life study, we established that there was no additional benefit of RT in GC patients who underwent D2 dissection.

How to cite this article: Yekedüz E, Doğan İ, Birgi SD, et al. Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study. Euroasian J Hepato-Gastroenterol 2021;11(2):51-58.

背景:放疗在胃癌(GC)辅助治疗中的作用尚不明确。本研究旨在评估放疗在胃癌辅助治疗中的额外益处。材料和方法:在这项回顾性队列研究中,我们纳入了2004年1月至2019年12月期间接受D2解剖的230例胃腺癌患者。未切除R0的患者,在手术中进行了转移性切除,并接受了新辅助治疗。共同主要终点是总生存期(OS)和无病生存期(DFS)。次要终点是局部和远处转移风险以及导致停止治疗的不良事件(ae)。结果:放化疗组(CRT)和化疗组(ChT)分别纳入166例和64例患者。CRT组和ChT组的中位OS分别为135.8个月(四分位间距:99.4-172.2)和97个月(四分位间距:59.7-134.3)。两组间OS差异无统计学意义(p = 0.3)。两组的局部或远处复发率相似。CRT组导致停药的ae高于ChT组(13.2 vs 9.3%),两组间差异无统计学意义(p = 0.4)。结论:在这项现实生活中的研究中,我们确定在接受D2剥离的GC患者中,RT没有额外的益处。如何引用本文:yeked z E, Doğan İ, Birgi SD, et al。D2夹层时代胃癌的辅助治疗:来自多中心回顾性队列研究的现实经验。中华肝病与胃肠病杂志;2011;11(2):51-58。
{"title":"Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study.","authors":"Emre Yekedüz,&nbsp;İzzet Doğan,&nbsp;Sümerya D Birgi,&nbsp;Metin Keskin,&nbsp;Şule Karaman,&nbsp;Güngör Utkan,&nbsp;Senem Karabulut,&nbsp;Sancar Bayar,&nbsp;Hakan Akbulut,&nbsp;Salim Demirci,&nbsp;Serap Akyürek,&nbsp;Yüksel Ürün","doi":"10.5005/jp-journals-10018-1343","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1343","url":null,"abstract":"<p><strong>Background: </strong>The role of radiotherapy in the adjuvant treatment of gastric cancer (GC) remains to be elucidated. This study aimed to assess the additional benefit of radiotherapy in the adjuvant treatment of GC.</p><p><strong>Materials and methods: </strong>In this retrospective cohort study, we included 230 gastric adenocarcinoma patients who underwent D2 dissection between January 2004 and December 2019. Patients without R0 resection, who underwent metastasectomy at surgery, and treated with the neoadjuvant treatment were excluded. The co-primary endpoints were overall survival (OS) and disease-free survival (DFS). The secondary endpoints were the locoregional and distant metastasis risk and adverse events (AEs) leading to treatment discontinuation.</p><p><strong>Results: </strong>One hundred and sixty-six and 64 patients were included in the chemoradiotherapy (CRT) and chemotherapy (ChT) arms, respectively. The median OS was 135.8 months [interquartile range (IQR): 99.4-172.2] and 97 months (IQR: 59.7-134.3) in the CRT and the ChT arms, respectively. No statistical significance was observed between the arms in OS (<i>p</i> = 0.3). Locoregional or distant recurrence rates were similar in each group. AEs leading to treatment discontinuation were higher in the CRT arm than in the ChT arm (13.2 vs 9.3%), and the difference between the arms was not statistically significant (<i>p</i> = 0.4).</p><p><strong>Conclusion: </strong>In this real-life study, we established that there was no additional benefit of RT in GC patients who underwent D2 dissection.</p><p><strong>How to cite this article: </strong>Yekedüz E, Doğan İ, Birgi SD, <i>et al</i>. Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study. Euroasian J Hepato-Gastroenterol 2021;11(2):51-58.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"11 2","pages":"51-58"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f3/bb/ejohg-11-51.PMC8566162.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39630933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clinical Features and Pathophysiological Mechanisms of COVID-19-associated Gastrointestinal Manifestations. 新冠肺炎相关胃肠道表现的临床特征及病理生理机制
Pub Date : 2021-07-01 DOI: 10.5005/jp-journals-10018-1347
Abdullah Tarık Aslan, Halis Şimşek

Aim and objective: According to the literature, gastrointestinal (GI) involvement may have a remarkable influence on the course of coronavirus disease-2019 (COVID-19). Our aim with this article is to appraise clinical characteristics and presumptive biological mechanisms of digestive tract involvement of COVID-19.

Background: In this review article, the English language literature was reviewed by using PubMed and MEDLINE databases, up to February 2021.

Review results: The patients with GI involvement are generally presented with diarrhea, nausea/vomiting, anorexia, abdominal pain, and rarely GI bleeding. However, frequencies of these manifestations are diverse in studies published so far, depending on the countries where the studies were conducted, characteristics of the study populations, and methodological differences. Several studies proved that this novel coronavirus gets into the enterocytes by attaching to angiotensin-converting enzyme 2 receptor. Some of them have shown a direct viral invasion and replication of the virus within enterocytes. Along with detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients' fecal materials, all these results explicitly indicate that the virus has the capability to invade the GI system. These findings may represent a potential risk indicator for fecal-oral spread of the virus. Although pathophysiology of COVID-19 associated GI manifestations remains elusive, direct viral damage, dysfunction in renin-angiotensin-aldosterone system, effects of gut-lung axis, and GI tract microbiome dysbiosis have been proposed as culprit mechanisms of the GI symptoms and inflammatory response.

Conclusion: The patients with COVID-19 can be presented with diverse clinical manifestations including the GI symptoms. Understanding the actual impact of the virus on the GI tract depends on uncovering the pathophysiology of COVID-19.

Clinical significance: GI involvement of COVID-19 appears to be crucial not only for its clinical consequences but also for its impacts on public health and prevention.

How to cite this article: Aslan AT, Şimşek H. Clinical Features and Pathophysiological Mechanisms of COVID-19-associated Gastrointestinal Manifestations. Euroasian J Hepato-Gastroenterol 2021;11(2):81-86.

目的与目的:文献显示,胃肠道(GI)受累可能对冠状病毒病-2019 (COVID-19)的病程有显著影响。我们这篇文章的目的是评估COVID-19累及消化道的临床特征和可能的生物学机制。背景:在这篇综述文章中,使用PubMed和MEDLINE数据库对截至2021年2月的英文文献进行了综述。回顾结果:累及胃肠道的患者通常表现为腹泻、恶心/呕吐、厌食、腹痛,很少有消化道出血。然而,在迄今发表的研究中,这些表现的频率各不相同,这取决于进行研究的国家、研究人群的特征和方法差异。几项研究证明,这种新型冠状病毒通过附着在血管紧张素转换酶2受体上进入肠细胞。其中一些已经显示出病毒在肠细胞内的直接入侵和复制。加上在患者粪便中检测到严重急性呼吸综合征冠状病毒2型(SARS-CoV-2),这些结果都明确表明该病毒具有入侵胃肠道系统的能力。这些发现可能是该病毒粪口传播的潜在风险指标。尽管COVID-19相关胃肠道表现的病理生理机制尚不明确,但直接病毒损伤、肾素-血管紧张素-醛固酮系统功能障碍、肠-肺轴的影响以及胃肠道微生物群失调被认为是胃肠道症状和炎症反应的罪魁祸首机制。结论:新型冠状病毒肺炎患者可表现出包括胃肠道症状在内的多种临床表现。了解病毒对胃肠道的实际影响取决于揭示COVID-19的病理生理学。临床意义:COVID-19涉及胃肠道似乎不仅对其临床后果至关重要,而且对公共卫生和预防的影响也至关重要。本文来源:Aslan AT, Şimşek H.新冠肺炎相关胃肠道表现的临床特征及病理生理机制。中华肝病与胃肠病杂志;2011;11(2):81-86。
{"title":"Clinical Features and Pathophysiological Mechanisms of COVID-19-associated Gastrointestinal Manifestations.","authors":"Abdullah Tarık Aslan,&nbsp;Halis Şimşek","doi":"10.5005/jp-journals-10018-1347","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1347","url":null,"abstract":"<p><strong>Aim and objective: </strong>According to the literature, gastrointestinal (GI) involvement may have a remarkable influence on the course of coronavirus disease-2019 (COVID-19). Our aim with this article is to appraise clinical characteristics and presumptive biological mechanisms of digestive tract involvement of COVID-19.</p><p><strong>Background: </strong>In this review article, the English language literature was reviewed by using PubMed and MEDLINE databases, up to February 2021.</p><p><strong>Review results: </strong>The patients with GI involvement are generally presented with diarrhea, nausea/vomiting, anorexia, abdominal pain, and rarely GI bleeding. However, frequencies of these manifestations are diverse in studies published so far, depending on the countries where the studies were conducted, characteristics of the study populations, and methodological differences. Several studies proved that this novel coronavirus gets into the enterocytes by attaching to angiotensin-converting enzyme 2 receptor. Some of them have shown a direct viral invasion and replication of the virus within enterocytes. Along with detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients' fecal materials, all these results explicitly indicate that the virus has the capability to invade the GI system. These findings may represent a potential risk indicator for fecal-oral spread of the virus. Although pathophysiology of COVID-19 associated GI manifestations remains elusive, direct viral damage, dysfunction in renin-angiotensin-aldosterone system, effects of gut-lung axis, and GI tract microbiome dysbiosis have been proposed as culprit mechanisms of the GI symptoms and inflammatory response.</p><p><strong>Conclusion: </strong>The patients with COVID-19 can be presented with diverse clinical manifestations including the GI symptoms. Understanding the actual impact of the virus on the GI tract depends on uncovering the pathophysiology of COVID-19.</p><p><strong>Clinical significance: </strong>GI involvement of COVID-19 appears to be crucial not only for its clinical consequences but also for its impacts on public health and prevention.</p><p><strong>How to cite this article: </strong>Aslan AT, Şimşek H. Clinical Features and Pathophysiological Mechanisms of COVID-19-associated Gastrointestinal Manifestations. Euroasian J Hepato-Gastroenterol 2021;11(2):81-86.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"11 2","pages":"81-86"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/65/ejohg-11-81.PMC8566155.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39739564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Wilson's Disease and Hyperornithinemia-hyperammonemia-homocitrullinuria Syndrome in a Child: A Case Report with Lessons Learned! 儿童威尔逊氏病和高鸟氨酸血症-高氨血症-高糖氨酸尿综合征:一例报告与经验教训!
Pub Date : 2021-07-01 DOI: 10.5005/jp-journals-10018-1351
Meranthi Fernando, Suresh Vijay, Saikat Santra, Mary A Preece, Rachel Brown, Astor Rodrigues, Girish L Gupte

Background: Wilson's disease (WD) is a rare disorder of copper toxicosis. Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is even rarer. The coexistence of these two disorders and their clinical implications are not yet reported. We report on a child who succumbed to death due to liver disease caused by both disorders, documenting their disease-causing mutations and highlighting the lessons learnt out of this case.

Case description: A child who was diagnosed to have WD soon after birth due to known parental heterozygosity was later found to have developmental delay, seizures, and hyperammonemia. Subsequent evaluation confirmed hyperornithinemia-hyperammonamia-homocitrullinuria (HHH) syndrome as a comorbidity. Though this child was commenced on medical treatment for both the metabolic diseases since early life, his liver disease was rapidly progressive requiring a liver transplant (LTx) at 6-years. He died in the posttransplant period possibly due to sepsis and hidden metabolic consequences.

Conclusion: This case highlights that co-occurrence of WD and HHH syndrome would cause progressive liver disease despite medical treatment. Hence, the close clinical follow-up and early LTx would be warranted.

How to cite this article: Fernando M, Vijay S, Santra S, et al. Wilson's Disease and Hyperornithinemia-hyperammonemia-homocitrullinuria Syndrome in a Child: A Case Report with Lessons Learned! Euroasian J Hepato-Gastroenterol 2021;11(2):100-102.

背景:威尔逊病(WD)是一种罕见的铜中毒疾病。高鸟氨酸血症-高氨血症-高氮氨酸尿(HHH)综合征更为罕见。这两种疾病的共存及其临床意义尚未报道。我们报告了一名因这两种疾病引起的肝脏疾病而死亡的儿童,记录了他们的致病突变,并强调了从该病例中吸取的教训。病例描述:一名儿童在出生后不久因已知亲本杂合性被诊断为WD,后来发现有发育迟缓、癫痫发作和高氨血症。随后的评估证实高鸟氨酸血症-高氨血症-高氮尿(HHH)综合征是一种合并症。虽然这个孩子从小就开始治疗这两种代谢疾病,但他的肝脏疾病进展迅速,在6岁时需要肝移植(LTx)。他在移植后死亡,可能是由于败血症和潜在的代谢后果。结论:本病例强调了WD和HHH综合征的共存,即使药物治疗也会导致肝脏疾病的进展。因此,密切的临床随访和早期LTx是必要的。如何引用本文:Fernando M, Vijay S, Santra S等。儿童威尔逊氏病和高鸟氨酸血症-高氨血症-高糖氨酸尿综合征:一例报告与经验教训!中华肝病杂志;2011;11(2):100-102。
{"title":"Wilson's Disease and Hyperornithinemia-hyperammonemia-homocitrullinuria Syndrome in a Child: A Case Report with Lessons Learned!","authors":"Meranthi Fernando,&nbsp;Suresh Vijay,&nbsp;Saikat Santra,&nbsp;Mary A Preece,&nbsp;Rachel Brown,&nbsp;Astor Rodrigues,&nbsp;Girish L Gupte","doi":"10.5005/jp-journals-10018-1351","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1351","url":null,"abstract":"<p><strong>Background: </strong>Wilson's disease (WD) is a rare disorder of copper toxicosis. Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is even rarer. The coexistence of these two disorders and their clinical implications are not yet reported. We report on a child who succumbed to death due to liver disease caused by both disorders, documenting their disease-causing mutations and highlighting the lessons learnt out of this case.</p><p><strong>Case description: </strong>A child who was diagnosed to have WD soon after birth due to known parental heterozygosity was later found to have developmental delay, seizures, and hyperammonemia. Subsequent evaluation confirmed hyperornithinemia-hyperammonamia-homocitrullinuria (HHH) syndrome as a comorbidity. Though this child was commenced on medical treatment for both the metabolic diseases since early life, his liver disease was rapidly progressive requiring a liver transplant (LTx) at 6-years. He died in the posttransplant period possibly due to sepsis and hidden metabolic consequences.</p><p><strong>Conclusion: </strong>This case highlights that co-occurrence of WD and HHH syndrome would cause progressive liver disease despite medical treatment. Hence, the close clinical follow-up and early LTx would be warranted.</p><p><strong>How to cite this article: </strong>Fernando M, Vijay S, Santra S, <i>et al</i>. Wilson's Disease and Hyperornithinemia-hyperammonemia-homocitrullinuria Syndrome in a Child: A Case Report with Lessons Learned! Euroasian J Hepato-Gastroenterol 2021;11(2):100-102.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"11 2","pages":"100-102"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/00/ejohg-11-100.PMC8566159.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39630190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Primary Intestinal Lymphoma: Clinicopathological Characteristics of 55 Patients. 原发性肠淋巴瘤55例临床病理分析
Pub Date : 2021-07-01 DOI: 10.5005/jp-journals-10018-1345
Renuka Malipatel, Mallikarjun Patil, Pritilata Rout, Marjorie Correa, Harshad Devarbhavi

Introduction: Gastrointestinal (GI) tract is the most common site of extranodal lymphoma accounting for 30-40% of the cases. In Western countries, stomach is the most common site of GI lymphoma, whereas in the Middle East and Mediterranean countries, small intestine is commonly involved. Studies about primary intestinal lymphoma (PIL) are heterogeneous in anatomical distribution, presentation, and histological subtypes. The present study was aimed at studying the anatomical distribution, histological subtypes, and clinical characteristics at tertiary care centers.

Materials and methods: The present study was retrospective, conducted between 2006 and 2020. Patient's data were collected from institutional medical records. PIL was diagnosed by Lewin's criteria. After histological diagnosis, PIL was classified as per the World Health Organization (WHO) criteria and staging was done according to the Ann Arbor classification as modified by Musshoff.

Results: A total of 941 lymphoma cases were diagnosed during the study period between 2006 and 2020 consisting of 238 Hodgkin's lymphoma and 703 non-Hodgkin's lymphoma (NHL) cases. PIL constituted 5.8% of all lymphoma cases (55 out of 941) and 50.9% (55 of 108) of all primary GI lymphoma. Median age at diagnosis was 44 years and comprised predominantly males (85.45%). Diffuse large B-cell lymphoma (DLBCL) and mucosa-associated lymphoid tissue (MALT) lymphoma were the most common histological subtype (78%) seen. Two patients with primary Hodgkin's lymphoma involving the intestine were seen. T-cell lymphoma was seen in three (5.4%) patients. Ileocecal region was the most common site involved (27%). The common presenting complaints were intestinal obstruction (40%) requiring surgical resection and abdominal pain (32%). Majority of the patients presented in the early stages (I and II).

Conclusion: Our study demonstrates the pattern of distribution and various histological subtypes of PIL including the rare variants like primary intestinal Hodgkin's lymphoma. Relatively more number of patients presented with intestinal obstruction requiring surgery in comparison with other studies.

How to cite this article: Malipatel R, Patil M, Rout P, et al. Primary Intestinal Lymphoma: Clinicopathological Characteristics of 55 Patients. Euroasian J Hepato-Gastroenterol 2021;11(2):71-75.

胃肠道是结外淋巴瘤最常见的部位,约占病例的30-40%。在西方国家,胃是胃肠道淋巴瘤最常见的部位,而在中东和地中海国家,小肠通常受累。关于原发性肠淋巴瘤(PIL)的研究在解剖分布、表现和组织学亚型上是不均匀的。本研究旨在研究三级医疗中心的解剖分布、组织学亚型和临床特征。材料和方法:本研究为回顾性研究,研究时间为2006年至2020年。患者数据从机构医疗记录中收集。根据Lewin的标准诊断为PIL。经组织学诊断后,按世界卫生组织(WHO)标准对PIL进行分类,按Musshoff改良的Ann Arbor分类法进行分期。结果:2006 - 2020年共诊断淋巴瘤941例,其中霍奇金淋巴瘤238例,非霍奇金淋巴瘤703例。PIL占所有淋巴瘤病例的5.8%(941例中55例),占所有原发性GI淋巴瘤病例的50.9%(108例中55例)。诊断时中位年龄44岁,以男性为主(85.45%)。弥漫性大b细胞淋巴瘤(DLBCL)和粘膜相关淋巴组织淋巴瘤(MALT)是最常见的组织学亚型(78%)。2例原发性霍奇金淋巴瘤累及肠道。t细胞淋巴瘤3例(5.4%)。回盲区是最常见的受累部位(27%)。常见的主诉是需要手术切除的肠梗阻(40%)和腹痛(32%)。结论:我们的研究显示了PIL的分布模式和不同的组织学亚型,包括罕见的变异,如原发性肠道霍奇金淋巴瘤。与其他研究相比,出现肠梗阻需要手术的患者相对较多。本文引用方式:Malipatel R, Patil M, Rout P等。原发性肠淋巴瘤55例临床病理分析中华肝病与胃肠病杂志;2011;11(2):71-75。
{"title":"Primary Intestinal Lymphoma: Clinicopathological Characteristics of 55 Patients.","authors":"Renuka Malipatel,&nbsp;Mallikarjun Patil,&nbsp;Pritilata Rout,&nbsp;Marjorie Correa,&nbsp;Harshad Devarbhavi","doi":"10.5005/jp-journals-10018-1345","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1345","url":null,"abstract":"<p><strong>Introduction: </strong>Gastrointestinal (GI) tract is the most common site of extranodal lymphoma accounting for 30-40% of the cases. In Western countries, stomach is the most common site of GI lymphoma, whereas in the Middle East and Mediterranean countries, small intestine is commonly involved. Studies about primary intestinal lymphoma (PIL) are heterogeneous in anatomical distribution, presentation, and histological subtypes. The present study was aimed at studying the anatomical distribution, histological subtypes, and clinical characteristics at tertiary care centers.</p><p><strong>Materials and methods: </strong>The present study was retrospective, conducted between 2006 and 2020. Patient's data were collected from institutional medical records. PIL was diagnosed by Lewin's criteria. After histological diagnosis, PIL was classified as per the World Health Organization (WHO) criteria and staging was done according to the Ann Arbor classification as modified by Musshoff.</p><p><strong>Results: </strong>A total of 941 lymphoma cases were diagnosed during the study period between 2006 and 2020 consisting of 238 Hodgkin's lymphoma and 703 non-Hodgkin's lymphoma (NHL) cases. PIL constituted 5.8% of all lymphoma cases (55 out of 941) and 50.9% (55 of 108) of all primary GI lymphoma. Median age at diagnosis was 44 years and comprised predominantly males (85.45%). Diffuse large B-cell lymphoma (DLBCL) and mucosa-associated lymphoid tissue (MALT) lymphoma were the most common histological subtype (78%) seen. Two patients with primary Hodgkin's lymphoma involving the intestine were seen. T-cell lymphoma was seen in three (5.4%) patients. Ileocecal region was the most common site involved (27%). The common presenting complaints were intestinal obstruction (40%) requiring surgical resection and abdominal pain (32%). Majority of the patients presented in the early stages (I and II).</p><p><strong>Conclusion: </strong>Our study demonstrates the pattern of distribution and various histological subtypes of PIL including the rare variants like primary intestinal Hodgkin's lymphoma. Relatively more number of patients presented with intestinal obstruction requiring surgery in comparison with other studies.</p><p><strong>How to cite this article: </strong>Malipatel R, Patil M, Rout P, <i>et al</i>. Primary Intestinal Lymphoma: Clinicopathological Characteristics of 55 Patients. Euroasian J Hepato-Gastroenterol 2021;11(2):71-75.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"11 2","pages":"71-75"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/ff/ejohg-11-71.PMC8566158.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39630936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
COVID-19 and LIVER DISEASES: Pandemic, Epidemic and Endemic COVID-19与肝脏疾病:大流行、流行和地方病
Pub Date : 2021-01-06 DOI: 10.5005/ejohg-10-2-iv
H. Ozkan, M. Mahtab, S. M. Akbar
{"title":"COVID-19 and LIVER DISEASES: Pandemic, Epidemic and Endemic","authors":"H. Ozkan, M. Mahtab, S. M. Akbar","doi":"10.5005/ejohg-10-2-iv","DOIUrl":"https://doi.org/10.5005/ejohg-10-2-iv","url":null,"abstract":"","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"44 1","pages":"00-00"},"PeriodicalIF":0.0,"publicationDate":"2021-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73421790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dynamic Intraductal Endoscopic Visualization of Right Hepatic Artery Pulsation Underlying Minor Vascular Impression of the Proximal Bile Duct. 胆管近端小血管印痕下右肝动脉搏动的管内内镜动态显示。
Pub Date : 2021-01-01 DOI: 10.5005/jp-journals-10018-1332
Vincent Zimmer

Right hepatic artery (RHA) syndrome is a well-recognized, though an uncommon cause of benign bile duct stricture, potentially simulating malignancy. Albeit the latter was not the case in this unique clinical report after cholangitis resolution and clearance of biliary sludge and debris, high-quality direct cholangioscopy (DC) illustration of the RHA overriding the proximal common bile duct with well visible arterial pulsation has not yet been reported before. Beyond its potential visual informativeness, this uncommon cholangioscopic documentation may provide key didactic advances in terms of intraductal visualization of the anatomy of the biliary tree. How to cite this article: Zimmer V. Dynamic Intraductal Endoscopic Visualization of Right Hepatic Artery Pulsation Underlying Minor Vascular Impression of the Proximal Bile Duct. Euroasian J Hepato-Gastroenterol 2021;11(1):41-42.

右肝动脉(RHA)综合征是一个公认的,虽然不常见的良性胆管狭窄的原因,潜在的模拟恶性肿瘤。尽管在胆管炎消退和胆道污泥和碎片清除后的独特临床报告中没有出现后者,但高质量的直接胆管镜(DC)显示RHA覆盖近端胆管并伴有明显的动脉搏动,此前尚未有报道。除了潜在的视觉信息外,这种不常见的胆道镜记录可能为胆道树的导管内解剖可视化提供关键的教学进展。如何引用这篇文章:Zimmer V.在胆管近端小血管印痕下的动态管内内镜下显示右肝动脉搏动。中华肝病与胃肠病杂志;2011;11(1):41-42。
{"title":"Dynamic Intraductal Endoscopic Visualization of Right Hepatic Artery Pulsation Underlying Minor Vascular Impression of the Proximal Bile Duct.","authors":"Vincent Zimmer","doi":"10.5005/jp-journals-10018-1332","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1332","url":null,"abstract":"<p><p>Right hepatic artery (RHA) syndrome is a well-recognized, though an uncommon cause of benign bile duct stricture, potentially simulating malignancy. Albeit the latter was not the case in this unique clinical report after cholangitis resolution and clearance of biliary sludge and debris, high-quality direct cholangioscopy (DC) illustration of the RHA overriding the proximal common bile duct with well visible arterial pulsation has not yet been reported before. Beyond its potential visual informativeness, this uncommon cholangioscopic documentation may provide key didactic advances in terms of intraductal visualization of the anatomy of the biliary tree. <b>How to cite this article:</b> Zimmer V. Dynamic Intraductal Endoscopic Visualization of Right Hepatic Artery Pulsation Underlying Minor Vascular Impression of the Proximal Bile Duct. Euroasian J Hepato-Gastroenterol 2021;11(1):41-42.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"11 1","pages":"41-42"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/cf/ejohg-11-41.PMC8286368.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39228243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lymph Node Ratio is an Important Prognostic Factor in Curatively Resected Gallbladder Carcinoma, Especially in Node-positive Patients: An Experience from Endemic Region in a Developing Country. 淋巴结比例是治疗性胆囊癌切除术的重要预后因素,尤其是淋巴结阳性患者:来自发展中国家流行地区的经验。
Pub Date : 2021-01-01 DOI: 10.5005/jp-journals-10018-1336
Shah Naveed, Hasina Qari, Cao M Thau, Pipit Burasakarn, Abdul W Mir, Brij Bhushan Panday

Background: Metastasis to lymph nodes is a bad prognostic factor in patients with gallbladder carcinoma who undergo radical cholecystectomy. During the past decade, studies have brought focus on lymph node ratio (LNR) as an additional valuable prognostic factor in these cases.Our research studied the factors that predicted the recurrence of disease and survival of patients with gallbladder carcinoma who were treated with surgical resection, concentrating especially on the lymph nodal status as a prognostic factor and LNR in node-positive T1-T3 cases.

Methods: In our hospital, Mahavir Cancer Institute and Research Centre, we reviewed retrospective data, from 2009 to 2014, of 60 patients who had undergone radical cholecystectomy for gallbladder carcinoma. We staged the patients as per the AJCC eight edition. Predictive factors that affect disease-free survival (DFS), like age, gender, postoperative complications, lymphovascular invasion (LVI) and perineural invasion (PVI), lymph node dissection, differentiation, T stage, N stage, number of lymph nodes involved, and LNR, were examined statistically.

Results: Lymph nodal involvement was found to be a principal predictive factor in cases in whom radical cholecystectomy was done. The number of lymph nodes dissected determined the prognosis in N0 cases. LNR was a strong prognostic factor for DFS in cases of curatively resected gallbladder cancer.

Conclusion: LNR is a strong predictive factor in radically resected gallbladder carcinoma cases.

How to cite this article: Naveed S, Qari H, Thau CM, et al. Lymph Node Ratio is an Important Prognostic Factor in Curatively Resected Gallbladder Carcinoma, Especially in Node-positive Patients: An Experience from Endemic Region in a Developing Country. Euroasian J Hepato-Gastroenterol 2021;11(1):1-5.

背景:胆囊癌患者行根治性胆囊切除术后,淋巴结转移是一个不良的预后因素。在过去的十年中,研究将淋巴结比例(LNR)作为这些病例的另一个有价值的预后因素。我们的研究探讨了胆囊癌手术切除患者疾病复发和生存的影响因素,重点关注淋巴结状态作为预后因素和淋巴结阳性T1-T3病例的LNR。方法:回顾性分析我院Mahavir癌症研究所和研究中心2009年至2014年60例胆囊癌根治性胆囊切除术患者的资料。我们按照AJCC第八版对病人进行了分类。对年龄、性别、术后并发症、淋巴血管侵袭(LVI)和神经周围侵袭(PVI)、淋巴结清扫、分化、T分期、N分期、受累淋巴结数、LNR等影响无病生存(DFS)的预测因素进行统计学分析。结果:淋巴结受累是行根治性胆囊切除术的主要预测因素。0例淋巴结清扫数决定预后。LNR是胆囊癌根治后DFS的重要预后因素。结论:LNR是胆囊癌根治性切除的重要预测因素。如何引用本文:Naveed S, Qari H, Thau CM等。淋巴结比例是治疗性胆囊癌切除术的重要预后因素,尤其是淋巴结阳性患者:来自发展中国家流行地区的经验。中华肝病杂志;2011;11(1):1-5。
{"title":"Lymph Node Ratio is an Important Prognostic Factor in Curatively Resected Gallbladder Carcinoma, Especially in Node-positive Patients: An Experience from Endemic Region in a Developing Country.","authors":"Shah Naveed,&nbsp;Hasina Qari,&nbsp;Cao M Thau,&nbsp;Pipit Burasakarn,&nbsp;Abdul W Mir,&nbsp;Brij Bhushan Panday","doi":"10.5005/jp-journals-10018-1336","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1336","url":null,"abstract":"<p><strong>Background: </strong>Metastasis to lymph nodes is a bad prognostic factor in patients with gallbladder carcinoma who undergo radical cholecystectomy. During the past decade, studies have brought focus on lymph node ratio (LNR) as an additional valuable prognostic factor in these cases.Our research studied the factors that predicted the recurrence of disease and survival of patients with gallbladder carcinoma who were treated with surgical resection, concentrating especially on the lymph nodal status as a prognostic factor and LNR in node-positive T1-T3 cases.</p><p><strong>Methods: </strong>In our hospital, Mahavir Cancer Institute and Research Centre, we reviewed retrospective data, from 2009 to 2014, of 60 patients who had undergone radical cholecystectomy for gallbladder carcinoma. We staged the patients as per the AJCC eight edition. Predictive factors that affect disease-free survival (DFS), like age, gender, postoperative complications, lymphovascular invasion (LVI) and perineural invasion (PVI), lymph node dissection, differentiation, T stage, N stage, number of lymph nodes involved, and LNR, were examined statistically.</p><p><strong>Results: </strong>Lymph nodal involvement was found to be a principal predictive factor in cases in whom radical cholecystectomy was done. The number of lymph nodes dissected determined the prognosis in N0 cases. LNR was a strong prognostic factor for DFS in cases of curatively resected gallbladder cancer.</p><p><strong>Conclusion: </strong>LNR is a strong predictive factor in radically resected gallbladder carcinoma cases.</p><p><strong>How to cite this article: </strong>Naveed S, Qari H, Thau CM, <i>et al.</i> Lymph Node Ratio is an Important Prognostic Factor in Curatively Resected Gallbladder Carcinoma, Especially in Node-positive Patients: An Experience from Endemic Region in a Developing Country. Euroasian J Hepato-Gastroenterol 2021;11(1):1-5.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"11 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/3b/ejohg-11-1.PMC8286361.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39227803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Exchange Transfusion for Hyperbilirubinemia among Term and Near Term in NICU of a Tertiary Care Hospital of Bangladesh: Findings from a Prospective Study. 孟加拉国一家三级医院新生儿重症监护室中足月和近足月高胆红素血症调换输血:一项前瞻性研究的结果。
Pub Date : 2021-01-01 DOI: 10.5005/jp-journals-10018-1331
Sanjoy K Dey, Sultana Jahan, Ismat Jahan, Mohammad S Islam, Mohammad Kh Shabuj, Mohammod Shahidullah

Background: Exchange transfusion in newborns is recommended as emergency management of hyperbilirubinemia to prevent bilirubin encephalopathy and kernicterus.

Aim: This study aimed to determine the frequency and document common side effects of exchange transfusion and outcomes of newborns requiring exchange transfusion.

Materials and methods: This prospective study was done in the Neonatal Intensive Care Unit (NICU) of Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh, from January 2016 to December 2019. Information was obtained regarding maternal details, newborn demographics, and clinical status. Blood grouping and Rh typing were done for both mothers and newborns. In all newborns, pre-exchange complete blood count, peripheral blood film, Coombs test, reticulocyte count, serum bilirubin and post-exchange serum bilirubin, hemoglobin, random blood sugar, serum electrolyte, and calcium were done. G6PD level was done wherever suspected. Frequency, maternal and neonatal factors, indications, and outcomes were analyzed.

Results: Among 839 admitted cases of unconjugated hyperbilirubinemia, 41 patients (4.9%) required exchange transfusion. Most of the babies were inborn (90.2%). Ninety-five percent of mothers received regular antenatal care; among them, 76.3% had bad obstetric history. Only 36.6% of mothers received anti-D in previous pregnancy. None had sonographic findings of hydrops. The commonest indication was Rh incompatibility (80.5%). Coombs test was positive in 58.5% of cases. Mean pre-exchange TSB was 9.44 ± 6.4, and post-exchange TSB was 4.41 ± 2.59. The commonest adverse events noted were hyperglycemia (51.2%), sepsis (19.5%), anemia requiring top-up transfusion (17.1%), and hypocalcemia (14.6%). There were no catheter-related complications. Bilirubin encephalopathy was present in 4.9% of cases. There was one mortality but not due to the procedure.

Conclusion: Exchange transfusion was required among 4.9% of the admitted newborns with unconjugated hyperbilirubinemia. The common adverse effects were hyperglycemia and sepsis. The commonest indication was Rh incompatibility (80.5%). Overall outcome after exchange transfusion was favorable.

How to cite this article: Dey SK, Jahan S, Jahan I, et al. Exchange Transfusion for Hyperbilirubinemia among Term and Near Term in NICU of a Tertiary Care Hospital of Bangladesh: Findings from a Prospective Study. Euroasian J Hepato-Gastroenterol 2021;11(1):21-26.

背景:新生儿换血被推荐作为高胆红素血症的紧急管理,以防止胆红素脑病和核黄疸。目的:本研究旨在确定换血的频率,并记录换血的常见副作用和新生儿需要换血的结局。材料与方法:本前瞻性研究于2016年1月至2019年12月在孟加拉国Bangabandhu Sheikh Mujib医科大学(BSMMU)新生儿重症监护病房(NICU)完成。获得了有关产妇细节、新生儿人口统计和临床状况的信息。对母亲和新生儿进行了血型和Rh型分析。对所有新生儿进行交换前全血细胞计数、外周血膜、Coombs试验、网状红细胞计数、血清胆红素和交换后血清胆红素、血红蛋白、随机血糖、血清电解质和钙的检测。疑似处均行G6PD水平检测。分析频率、孕产妇和新生儿因素、适应症和结局。结果:839例非结合性高胆红素血症患者中有41例(4.9%)需要换血。绝大多数是出生的(90.2%)。95%的母亲得到定期产前保健;其中76.3%有不良产科史。只有36.6%的母亲在怀孕前接受过抗d治疗。超声检查均未发现积液。最常见的适应症是Rh不相容(80.5%)。Coombs试验阳性的病例占58.5%。交换前TSB平均值为9.44±6.4,交换后TSB平均值为4.41±2.59。最常见的不良事件是高血糖(51.2%)、败血症(19.5%)、需要补充输血的贫血(17.1%)和低钙血症(14.6%)。无导管相关并发症。4.9%的病例存在胆红素脑病。有一人死亡,但不是手术造成的。结论:非结合性高胆红素血症住院新生儿中有4.9%需要换血。常见的不良反应是高血糖和败血症。最常见的适应症是Rh不相容(80.5%)。换血后的总体结果是有利的。文章出处:Dey SK, Jahan S, Jahan I等。孟加拉国一家三级医院新生儿重症监护室中足月和近足月高胆红素血症调换输血:一项前瞻性研究的结果。中华肝病杂志;2011;11(1):21-26。
{"title":"Exchange Transfusion for Hyperbilirubinemia among Term and Near Term in NICU of a Tertiary Care Hospital of Bangladesh: Findings from a Prospective Study.","authors":"Sanjoy K Dey,&nbsp;Sultana Jahan,&nbsp;Ismat Jahan,&nbsp;Mohammad S Islam,&nbsp;Mohammad Kh Shabuj,&nbsp;Mohammod Shahidullah","doi":"10.5005/jp-journals-10018-1331","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1331","url":null,"abstract":"<p><strong>Background: </strong>Exchange transfusion in newborns is recommended as emergency management of hyperbilirubinemia to prevent bilirubin encephalopathy and kernicterus.</p><p><strong>Aim: </strong>This study aimed to determine the frequency and document common side effects of exchange transfusion and outcomes of newborns requiring exchange transfusion.</p><p><strong>Materials and methods: </strong>This prospective study was done in the Neonatal Intensive Care Unit (NICU) of Bangabandhu Sheikh Mujib Medical University (BSMMU), Bangladesh, from January 2016 to December 2019. Information was obtained regarding maternal details, newborn demographics, and clinical status. Blood grouping and Rh typing were done for both mothers and newborns. In all newborns, pre-exchange complete blood count, peripheral blood film, Coombs test, reticulocyte count, serum bilirubin and post-exchange serum bilirubin, hemoglobin, random blood sugar, serum electrolyte, and calcium were done. G6PD level was done wherever suspected. Frequency, maternal and neonatal factors, indications, and outcomes were analyzed.</p><p><strong>Results: </strong>Among 839 admitted cases of unconjugated hyperbilirubinemia, 41 patients (4.9%) required exchange transfusion. Most of the babies were inborn (90.2%). Ninety-five percent of mothers received regular antenatal care; among them, 76.3% had bad obstetric history. Only 36.6% of mothers received anti-D in previous pregnancy. None had sonographic findings of hydrops. The commonest indication was Rh incompatibility (80.5%). Coombs test was positive in 58.5% of cases. Mean pre-exchange TSB was 9.44 ± 6.4, and post-exchange TSB was 4.41 ± 2.59. The commonest adverse events noted were hyperglycemia (51.2%), sepsis (19.5%), anemia requiring top-up transfusion (17.1%), and hypocalcemia (14.6%). There were no catheter-related complications. Bilirubin encephalopathy was present in 4.9% of cases. There was one mortality but not due to the procedure.</p><p><strong>Conclusion: </strong>Exchange transfusion was required among 4.9% of the admitted newborns with unconjugated hyperbilirubinemia. The common adverse effects were hyperglycemia and sepsis. The commonest indication was Rh incompatibility (80.5%). Overall outcome after exchange transfusion was favorable.</p><p><strong>How to cite this article: </strong>Dey SK, Jahan S, Jahan I, <i>et al.</i> Exchange Transfusion for Hyperbilirubinemia among Term and Near Term in NICU of a Tertiary Care Hospital of Bangladesh: Findings from a Prospective Study. Euroasian J Hepato-Gastroenterol 2021;11(1):21-26.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"11 1","pages":"21-26"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b4/6e/ejohg-11-21.PMC8286359.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39228240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Updates on the Diagnosis and Management of Hepatocellular Carcinoma. 肝细胞癌的诊断和治疗进展。
Pub Date : 2021-01-01 DOI: 10.5005/jp-journals-10018-1335
Aimun Raees, Muhammad Kamran, Hasan Özkan, Wasim Jafri

Introduction: Globally, the incidence, as well as mortality, related to hepatocellular carcinoma (HCC) is on the rise, owing to relatively few curative options. Underlying cirrhosis is the most common etiology leading to HCC, but risk factors of cirrhosis show great regional variability. Over the years, there has been a steady development in the diagnostic and therapeutic modalities of HCC, including the availability of a wide range of systemic chemotherapeutic agents. We aim to review the recent advancements in the diagnostic and therapeutic strategies for HCC.

Methodology: The literature search was done using databases PubMed, Cochrane, and Science Direct, and the latest relevant articles were reviewed.

Findings: Screening of HCC is a pivotal step in the early diagnosis of the disease. Current guidelines recommend using ultrasound and alfa fetoprotein but various new biomarkers are under active research that might aid in diagnosing very small tumors, not picked up by the current screening methods. Treatment options are decided based upon the overall performance of the patient and the extent of the disease, as per the Barcelona classification. There are very few options that offer a cure for the disease, ranging from liver resection and transplantation to tumor ablation. Downstaging has proven to have a significant role in the course of the disease. An attempt to control the disease can be made via radiological interventions, such as transarterial chemoembolization, transarterial radioembolization, or radiation therapy. For advanced disease, sorafenib used to be the only option until a couple of years ago. Recently, many other systemic agents have received approval as first-line and second-line therapies for HCC. Genomics is an area of active clinical research as understanding the mutations and genomics involved in the evolution of HCC might lead to a breakthrough therapy.

How to cite this article: Raees A, Kamran M, Özkan H, et al. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepato-Gastroenterol 2021;11(1):32-40.

导读:在全球范围内,由于治疗选择相对较少,与肝细胞癌(HCC)相关的发病率和死亡率正在上升。原发性肝硬化是导致HCC最常见的病因,但肝硬化的危险因素表现出很大的区域差异。多年来,HCC的诊断和治疗方式稳步发展,包括广泛的全身化疗药物的可用性。我们旨在回顾HCC诊断和治疗策略的最新进展。方法:使用PubMed、Cochrane和Science Direct数据库进行文献检索,并对最新的相关文章进行综述。结果:HCC筛查是早期诊断的关键一步。目前的指导方针建议使用超声波和甲胎蛋白,但各种新的生物标志物正在积极研究中,可能有助于诊断非常小的肿瘤,目前的筛查方法无法检测到。根据巴塞罗那分类,治疗方案是根据患者的整体表现和疾病程度来决定的。只有很少的选择可以治愈这种疾病,从肝脏切除和移植到肿瘤消融。降低分期已被证明在疾病的过程中起着重要作用。控制疾病的尝试可以通过放射干预,如经动脉化疗栓塞、经动脉放射栓塞或放射治疗。对于晚期疾病,索拉非尼曾经是唯一的选择,直到几年前。最近,许多其他全身性药物已被批准作为HCC的一线和二线治疗。基因组学是一个活跃的临床研究领域,因为了解HCC演变过程中的突变和基因组学可能会带来突破性的治疗。引用方式:Raees A, Kamran M, Özkan H,等。肝细胞癌的诊断和治疗进展。中华肝病杂志;2011;11(1):32-40。
{"title":"Updates on the Diagnosis and Management of Hepatocellular Carcinoma.","authors":"Aimun Raees,&nbsp;Muhammad Kamran,&nbsp;Hasan Özkan,&nbsp;Wasim Jafri","doi":"10.5005/jp-journals-10018-1335","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1335","url":null,"abstract":"<p><strong>Introduction: </strong>Globally, the incidence, as well as mortality, related to hepatocellular carcinoma (HCC) is on the rise, owing to relatively few curative options. Underlying cirrhosis is the most common etiology leading to HCC, but risk factors of cirrhosis show great regional variability. Over the years, there has been a steady development in the diagnostic and therapeutic modalities of HCC, including the availability of a wide range of systemic chemotherapeutic agents. We aim to review the recent advancements in the diagnostic and therapeutic strategies for HCC.</p><p><strong>Methodology: </strong>The literature search was done using databases PubMed, Cochrane, and Science Direct, and the latest relevant articles were reviewed.</p><p><strong>Findings: </strong>Screening of HCC is a pivotal step in the early diagnosis of the disease. Current guidelines recommend using ultrasound and alfa fetoprotein but various new biomarkers are under active research that might aid in diagnosing very small tumors, not picked up by the current screening methods. Treatment options are decided based upon the overall performance of the patient and the extent of the disease, as per the Barcelona classification. There are very few options that offer a cure for the disease, ranging from liver resection and transplantation to tumor ablation. Downstaging has proven to have a significant role in the course of the disease. An attempt to control the disease can be made via radiological interventions, such as transarterial chemoembolization, transarterial radioembolization, or radiation therapy. For advanced disease, sorafenib used to be the only option until a couple of years ago. Recently, many other systemic agents have received approval as first-line and second-line therapies for HCC. Genomics is an area of active clinical research as understanding the mutations and genomics involved in the evolution of HCC might lead to a breakthrough therapy.</p><p><strong>How to cite this article: </strong>Raees A, Kamran M, Özkan H, <i>et al.</i> Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepato-Gastroenterol 2021;11(1):32-40.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"11 1","pages":"32-40"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/1a/ejohg-11-32.PMC8286363.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39228242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Comparative Analysis of Early versus Late Laparoscopic Cholecystectomy Following Endoscopic Retrograde Cholangiopancreaticography in Cases of Cholelithiasis with Choledocholithiasis. 内镜逆行胆管胰胆管造影后早期与晚期腹腔镜胆囊切除术治疗胆石症合并胆总管结石的比较分析。
Pub Date : 2021-01-01 DOI: 10.5005/jp-journals-10018-1338
Apoorv Goel, Shyam Kothari, Roli Bansal

Introduction: A preferred treatment for cholelithiasis with choledocholithiasis is endoscopic retrograde cholangiopancreaticography (ERCP) followed by laparoscopic cholecystectomy (LC), which can be performed early (within 72 hours) or can be delayed for 6 to 8 weeks. This study is conducted to compare and analyze the outcome of early versus late LC following common bile duct (CBD) clearance by ERCP and determine the optimum timing for performing LC post-ERCP.

Materials and methods: This comparative analysis was conducted at St Joseph Hospital, Ghaziabad, from September 2019 to March 2021 on 89 cases of cholelithiasis with choledocholithiasis. Patients were divided into two groups. Group I (n = 45) patients underwent early LC within 72 hours post-ERCP and group II (n = 44) patients underwent late LC after an interval of 8 weeks. Various preoperative, perioperative, and postoperative clinical parameters like operative difficulty, complications, surgery duration, hospital stay, and conversion to open cholecystectomy were analyzed.

Results: There was no significant difference in demographic and laboratory findings in both groups. Group I patients had significantly shorter hospital stay and less operative difficulty. The duration of surgery was significantly low in group I. There was no significant difference in rate of conversion to open cholecystectomy.

Conclusion: Early LC post-ERCP is associated with short hospital stay and duration of surgery and less operative difficulty and complications. Therefore, we recommend that LC can be safely performed within 48 to 72 hours after ERCP.

How to cite this article: Goel A, Kothari S, Bansal R. Comparative Analysis of Early versus Late Laparoscopic Cholecystectomy Following Endoscopic Retrograde Cholangiopancreaticography in Cases of Cholelithiasis with Choledocholithiasis. Euroasian J Hepato-Gastroenterol 2021;11(1):11-13.

导言:胆管结石合并胆总管结石的首选治疗方法是内镜逆行胆管胰造影(ERCP),然后进行腹腔镜胆囊切除术(LC),可以早期(72小时内)进行,也可以延迟6 - 8周进行。本研究旨在比较和分析经ERCP清除总胆管(CBD)后早期和晚期LC的结果,并确定ERCP后LC的最佳时机。材料与方法:对2019年9月至2021年3月在加济阿巴德圣约瑟夫医院就诊的89例胆石症合并胆石管结石患者进行对比分析。患者分为两组。第一组(n = 45)患者在ercp后72小时内接受早期LC,第二组(n = 44)患者在间隔8周后接受晚期LC。分析术前、围手术期和术后的各种临床参数,如手术难度、并发症、手术时间、住院时间和转开腹胆囊切除术。结果:两组患者的人口学和实验室检查结果无显著差异。I组患者住院时间明显缩短,手术难度明显降低。ⅰ组手术时间明显较短,转开腹胆囊切除术率无显著差异。结论:ercp术后早期LC患者住院时间短,手术时间短,手术难度小,并发症少。因此,我们建议在ERCP术后48 - 72小时内行LC。Goel A, Kothari S, Bansal R.内镜逆行胆管胰胆管造影后早期与晚期腹腔镜胆囊切除术治疗胆石症合并胆总管结石的比较分析。中华肝病与胃肠病杂志;2011;11(1):11-13。
{"title":"Comparative Analysis of Early versus Late Laparoscopic Cholecystectomy Following Endoscopic Retrograde Cholangiopancreaticography in Cases of Cholelithiasis with Choledocholithiasis.","authors":"Apoorv Goel,&nbsp;Shyam Kothari,&nbsp;Roli Bansal","doi":"10.5005/jp-journals-10018-1338","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1338","url":null,"abstract":"<p><strong>Introduction: </strong>A preferred treatment for cholelithiasis with choledocholithiasis is endoscopic retrograde cholangiopancreaticography (ERCP) followed by laparoscopic cholecystectomy (LC), which can be performed early (within 72 hours) or can be delayed for 6 to 8 weeks. This study is conducted to compare and analyze the outcome of early versus late LC following common bile duct (CBD) clearance by ERCP and determine the optimum timing for performing LC post-ERCP.</p><p><strong>Materials and methods: </strong>This comparative analysis was conducted at St Joseph Hospital, Ghaziabad, from September 2019 to March 2021 on 89 cases of cholelithiasis with choledocholithiasis. Patients were divided into two groups. Group I (<i>n</i> = 45) patients underwent early LC within 72 hours post-ERCP and group II (<i>n</i> = 44) patients underwent late LC after an interval of 8 weeks. Various preoperative, perioperative, and postoperative clinical parameters like operative difficulty, complications, surgery duration, hospital stay, and conversion to open cholecystectomy were analyzed.</p><p><strong>Results: </strong>There was no significant difference in demographic and laboratory findings in both groups. Group I patients had significantly shorter hospital stay and less operative difficulty. The duration of surgery was significantly low in group I. There was no significant difference in rate of conversion to open cholecystectomy.</p><p><strong>Conclusion: </strong>Early LC post-ERCP is associated with short hospital stay and duration of surgery and less operative difficulty and complications. Therefore, we recommend that LC can be safely performed within 48 to 72 hours after ERCP.</p><p><strong>How to cite this article: </strong>Goel A, Kothari S, Bansal R. Comparative Analysis of Early versus Late Laparoscopic Cholecystectomy Following Endoscopic Retrograde Cholangiopancreaticography in Cases of Cholelithiasis with Choledocholithiasis. Euroasian J Hepato-Gastroenterol 2021;11(1):11-13.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"11 1","pages":"11-13"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/4a/ejohg-11-11.PMC8286358.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39227805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
期刊
Euroasian Journal of Hepato-Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1